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Natural Killer (NK) cells are a subset of innate lymphoid cells
specialized for cytotoxicity and production of inflammatory
cytokines such as IFNγ. As such, they are presumed to be impor-
tant for early control of infections with intracellular pathogens
and anti-tumor immunity. In addition, NK cells may help to
regulate placentation. The activation of effector functions is con-
trolled by the integration of signals from multiple receptors,
including not only activating and inhibitory NK cell receptors but
also receptors for cytokines such as IL-12, -15, -18. The Killer
cell Immunoglobulin-like Receptors (KIR) make up the largest
and by far most polymorphic human NK cell receptor family.
Underscoring the importance of KIR, their genetic variation is
associated with resistance to viruses such as HCV and HIV, auto-
immune diseases and reproductive success. To understand how
KIR influence health and reproduction, it is critical to know what
molecules they interact with. In this topic, leading experts pro-
vide an up-to-date overview of the known ligand specificities of
specific KIR.
Cresswell and deMars first showed in 1989 that transfection
of HLA class I molecules into class I-deficient cell lines reduced
their susceptibility to NK cell lysis (Harel-Bellan et al., 1986;
Quillet et al., 1988; Shimizu and DeMars, 1989; Storkus et al.,
1989). In this fashion, several HLA-B and -C alleles were identi-
fied as potential ligands for inhibitory NK cell receptors (Ciccone
et al., 1992; Colonna et al., 1993; Cella et al., 1994; Mandelboim
et al., 1996). Certain antibodies to NK cell surface molecules were
able to restore lysis of these HLA class I transfectants by NK cell
clones, allowing the definition of specificities of the receptors that
were blocked by the antibodies. Most of the antibodies (GL183,
EB6, CH-L, DX27, HP-3E4) bound 58 kDa receptors for HLA-C
variants characterized by either an Asparagine (C1) or a Lysine
(C2) at position 80 of their alpha-chains (Ciccone et al., 1992;
Moretta et al., 1993; Mandelboim et al., 1996), others (DX9, Z27)
a 70 kDa receptor for HLA-B (and some HLA-A) alleles carry-
ing the “Bw4-motif” (Litwin et al., 1994; Gumperz et al., 1995),
and a few (Q66, DX31) bound a 140 kDa homodimeric receptor
for HLA-A3 and -A11 (Pende et al., 1996). In many individuals
the antibodies recognizing inhibitory, 58 kDa receptors for HLA-
C also bound 50 kDa proteins from NK cell clones that acted as
activating receptors. Some of these receptors also bound HLA-C,
although weakly (Moretta et al., 1995).
Molecular cloning revealed that these receptors carried
1–3 immunoglobulin-like extracellular domains that were very
similar between different receptors (Colonna and Samaridis,
1995; D’Andrea et al., 1995;Wagtmann et al., 1995). Themain dif-
ferences between activating and inhibitory receptors were found
in their cytoplasmic tails. While the inhibitory receptors had a
long cytoplasmic tail with two ITIMs, allowing inhibitory sig-
naling (Burshtyn et al., 1996; Olcese et al., 1996), the activating
ones had a short cytoplasmic tail and a positively charged residue
in their transmembrane domain, allowing association with the
ITAM-bearing, signaling adapter DAP12 (Olcese et al., 1997;
Lanier et al., 1998). As scientists generally would rather share
toothbrushes than nomenclatures, for a while nomenclatures
from different laboratories co-existed. However, since the recep-
tors from different loci had remarkably high sequence similarity,
in some cases over 97%, and clearly belonged to the same receptor
family, it made sense to use a unified nomenclature that reflected
the receptors’ structures (Long et al., 1996). The receptors were
named KIR. KIR2D (50, 58 kDa) and KIR3D (70, 140 kDa),
refer to receptors with two or three IgSF domains, respectively.
Furthermore, L stands for receptors having long and S for
those having short cytoplasmic tails, consistent with the pres-
ence or absence of ITIMmotifs, respectively. Each KIR subfamily
is designated by an individual number, for example KIR2DS1
(Uhrberg et al., 1997; Valiante et al., 1997). The different KIR
loci can be found, together with discontinued names, on the
EBI-website: http://www.ebi.ac.uk/ipd/kir/genes.html (Robinson
et al., 2010).
Molecular cloning of the KIR paved the way for more detailed
genetic analyses. In the first instance, novel KIR were cloned from
cDNA libraries by homology. In this way KIR2DL4 (Selvakumar
et al., 1996), a receptor for HLA-G (Rajagopalan and Long, 1999;
Rajagopalan et al., 2005), was identified. The KIR locus, located
on chromosome 19q13.4, turned out to be densely packed with
KIR genes, oriented in a head-to-tail fashion (Martin et al.,
2000; Wilson et al., 2000). While some KIR haplotypes con-
tained few KIR genes, others hadmany. These efforts also revealed
the existence of additional KIR genes KIR2DL5A, KIR2DL5B,
KIR2DS5, KIR3DL3 (Vilches et al., 2000; Gomez-Lozano et al.,
2002), as well as several pseudogenes (KIR2DP1, KIR3DP1,
KIR1D). Common to virtually all haplotypes is the presence
of KIR3DL3 at the centromeric end of the locus, KIR2DL4
roughly in the center, and KIR3DL2 at the telomeric end. It
also quickly became clear that individual KIR genes display
extensive and functional polymorphism (O’Connor et al., 2007).
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The total number of functional KIR genes is 15, and well
over 50 alleles for individual genes have been described
(http://www.ebi.ac.uk/ipd/kir/alleles.html).
All this sequence information allowed the design of primer
sets to rapidly determine the presence or absence of specific KIR
genes (or alleles) in individuals (Uhrberg et al., 1997), which
in turn allowed genetic association studies. The first report of
this kind showed that the presence of KIR2DS2 was associated
with vasculitis in rheumatoid arthritis patients (Yen et al., 2001;
Majorczyk et al., 2007). Subsequent studies indicated a role for
KIR in psoriatric arthritis (Martin et al., 2002b; Nelson et al.,
2004; Williams et al., 2005), type I diabetes (van der Slik et al.,
2003, 2007) and several other auto-immune conditions. In line
with the notion that NK cells are important mediators of anti-
viral immunity, variation in KIR genes associated with the ability
to control infection with hepatitis C (Khakoo et al., 2004; Knapp
et al., 2010; Dring et al., 2011) and HIV (Martin et al., 2002a,
2007). The largest studies of this kind showed epistatic interaction
between KIR3DS1 and HLA-B in resistance to HIV progression
(Martin et al., 2002a, 2007). Finally, interactions between mater-
nal KIR and fetal HLA-C appeared to influence reproductive
success (Hiby et al., 2004, 2010).
Even though these studies demonstrated an important role for
KIR and KIR-HLA interactions in various diseases, the underly-
ing mechanisms are only beginning to be understood (Anfossi
et al., 2006; Alter et al., 2007, 2009; Ahlenstiel et al., 2008;
Hiby et al., 2010; O’Connor et al., 2011; Tarek et al., 2012).
A critical gap in our knowledge is the fact that ligands for
many activating, and some inhibitory, KIR are unknown. Of the
eight inhibitory KIR, five have well-characterized HLA speci-
ficities. Generally, KIR2DL1, KIR2DL2, KIR2DL3 together cover
all HLA-C alleles, KIR3DL1 binds a subset of HLA-B alleles,
and KIR3DL2 binds HLA-A3/A11 loaded with specific pep-
tides as well as homodimers of HLA-B27 heavy chains. These
binding profiles are supported in some cases by structural stud-
ies (Boyington et al., 2000; Fan et al., 2001; Campbell and
Purdy, 2011; Vivian et al., 2011). Of the six activating KIR,
only KIR2DS1 has a clearly defined specificity: C2 (Stewart
et al., 2005). In this topic, leading experts discuss the state
of the art in ligand identity for several KIR, in an effort to
shed light on the contribution of KIR-ligand interactions to dis-
ease (Cisneros et al., 2012; Korner and Altfeld, 2012; Moesta
and Parham, 2012; Rajagopalan and Long, 2012; Shaw and
Kollnberger, 2012).
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